Aeterna Zentaris Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement
QUEBEC CITY, April 27 /CNW Telbec/ - Aeterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ) (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, announced today that it has received a letter from the Nasdaq Stock Market notifying it that the closing price per share of the Company's common stock was above the US$1.00 minimum bid price for 10 consecutive trading days and that, as a result, the Company has regained compliance with Marketplace Rule 5450(a)(1) (the minimum bid price rule) as of Friday, April 23, 2010.
About Aeterna Zentaris Inc.
Aeterna Zentaris Inc. is a late-stage drug development company specialized in oncology and endocrine therapy News releases and additional information are available at www.aezsinc.com.For further information: Investor Relations: Ginette Vallières, Investor Relations Coordinator, (418) 652-8525 ext. 265, email@example.com; Media Relations: Paul Burroughs, Director of Communications, (418) 652-8525 ext. 406, firstname.lastname@example.org